International Blood Services Groups Eager to Commence Testing on Synthetic AFGP

VANCOUVER, British Columbia, May 6, 2005 (PRIMEZONE) -- Several major blood services groups have been carefully monitoring the extensive testing program currently being conducted by ProtoKinetix (OTCBB:PKTX) in Quebec. Due to the positive results ProtoKinetix has received on cell stabilization of red blood cells, platelets and tissues, the Company has been approached by two of the world's leading blood research facilities.

ProtoKinetix CEO, Dr. John Todd, expects to formalize an extensive agreement with a major European institution within the next month. This world recognized institution will be extending the testing of synthetic AFGP into the areas of the biological function of blood platelets, red blood cells and other blood components. Full details on this extensive program will be released as the agreement is finalized.

About ProtoKinetix

ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGP™ products.

For more detailed information, please visit our website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Ross L. Senior, President and CEO

ProtoKinetix Inc.
Investor Contact
Blair Henderson, 604-687-9887